|[September 04, 2014]
Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
PARIS --(Business Wire)--
Cellectis (Alternext: ALCLS.PA) (Paris:ALCLS) a leader in the
development of adoptive immunotherapies based on engineered allogeneic
CART cells (UCART) today announces that it has closed the sale of its
subsidiary Cellectis AB to Takara Bio Inc.
The financials terms have not been disclosed.
The Company now concentrates its activities in the field of oncology
through the development of Chimeric Antigen Receptor T-cell (CAR-T)
immunotherapy products generated through its allogeneic CAR-T platform,
both on its own as well as in partnership with Servier and Pfizer.
Cellectis is a biopharmaceutical company focused on oncology. The
company's mission is to develop a novel generation of therapy based on
engineered T-cells to treat cancer. Cellectis capitalizes on its 14
years of expertise i genome engineering, based on TALEN™, meganucleases
and the state-of-the-art electroporation technology Pulse (News - Alert) Agile, to
create a new generation of cancer immunotherapy for treating leukemias
and solid tumors. Cellectis adoptive cancer immunotherapy for chronic
and acute leukemias is based on the first allogeneic T-cell chimeric
antigen receptor (CAR) technology. CAR technologies are designed to
target surface antigens expressed on cells. These treatments reduce
toxicities associated with current chemotherapeutics and have the
potential for curative therapy. The Cellectis Group is focused on life
sciences and uses leading genome engineering technologies to build
innovative products in various fields and markets. Cellectis is listed
on the NYSE Alternext market (ticker: ALCLS). To find out more about us,
visit our website: www.cellectis.com
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company's
objectives based on the current expectations and assumptions of the
Company's management only and involve unforeseeable risk and
uncertainties that could cause the Company to fail to achieve the
objectives expressed by the forward-looking statements.
[ Back To Technology News's Homepage ]